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Abstract
Background: The formation of ADP-ribose polymers on target proteins by poly(ADP-ribose) polymerases serves a variety of
cell signaling functions. In addition, extensive activation of poly(ADP-ribose) polymerase-1 (PARP-1) is a dominant cause of
cell death in ischemia-reperfusion, trauma, and other conditions. Poly(ADP-ribose) glycohydrolase (PARG) degrades the
ADP-ribose polymers formed on acceptor proteins by PARP-1 and other PARP family members. PARG exists as multiple
isoforms with differing subcellular localizations, but the functional significance of these isoforms is uncertain.
Methods / Principal Findings: Primary mouse astrocytes were treated with an antisense phosphorodiamidate morpholino
oligonucleotide (PMO) targeted to exon 1 of full-length PARG to suppress expression of this nuclear-specific PARG isoform.
The antisense-treated cells showed down-regulation of both nuclear PARG immunoreactivity and nuclear PARG enzymatic
activity, without significant alteration in cytoplasmic PARG activity. When treated with the genotoxic agent MNNG to
induced PARP-1 activation, the antisense-treated cells showed a delayed rate of nuclear PAR degradation, reduced nuclear
condensation, and reduced cell death.
Conclusions/Significance: These results support a preferentially nuclear localization for full-length PARG, and suggest a key
role for this isoform in the PARP-1 cell death pathway.
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Introduction
Poly(ADP-ribose) polymerases consume NAD
+ to form
poly(ADP-ribose) (abbreviated as PAR) on acceptor proteins. This
post-translational modification influences protein-protein interac-
tions and serves a variety of cell signaling functions [1]. PARP-1,
the most abundant of the PARP family members, is localized to
the cell nucleus and is activated by DNA damage. Activated
PARP-1 forms PAR on histones, DNA repair enzymes, and
proteins involved in gene transcription [1]. PARP-1 also forms
PAR on PARP-1 itself, and this, under some conditions, can
reduce PARP-1 activity [2]. Extensive activation of PARP-1
occurs after ischemia-reperfusion, trauma, and other conditions
that cause DNA damage. In these settings, PARP-1 activation
leads to NAD
+ depletion, mitochondrial release of apoptosis-
inducing factor, and cell death [3–5].
The PAR generated by PARP-1 and other PARP isoforms is
degraded by poly(ADP-ribose) glycohydrolase (EC 3.2.1.143;
PARG), for which there is only one identified genetic loci [6,7].
The mitochondrial enzyme, ADP-ribosyl hydrolase, is also capable
of degrading PAR [8,9], but this is of uncertain biological
significance because cells with PARG gene deletion exhibit
massive PAR accumulation [6]. PARG activity can be suppressed
by pharmacological inhibitors or RNAi, both of which slow the
degradation of newly–formed PAR and block PARP-1 - mediated
cell death [10–17]. However, PARG gene deletion is embryonic
lethal in mice [6], and RNAi of the PARG orthologue in the
nematode increases sensitivity to ionizing radiation [18]. Mice
expressing a truncated PARG isoform lacking exons 2 and 3 in the
regulatory domain show different effects on PARP-1 - mediated
cell death in different experimental models [15,19,20].
The interpretation of these somewhat conflicting observations is
complicated by the existence of multiple PARG isoforms and the
differing subcellular localizations of these isoforms. The human
PARG gene can be processed into at least three splice variants
(Fig. 1A). These splice variants yield proteins of 111 kD, 102 kD,
and 99 kD. Of these, only the 111 kD isoform is preferentially
localized to the nucleus [21]. However, several catalytically active
smaller isoforms of PARG have been identified in cell lysates, and
these account for the majority of endogenous PARG activity [7]. It
remains uncertain whether these smaller species are splice variants
or proteolytic fragments. Although full-length PARG can be
demonstrated in cells transfected with PARG cDNA, endogenous
expression of full-length PARG is not usually detectable, due
either to low protein abundance or to rapid cleavage into smaller
active fragments [7,22–24].
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4896In the present study we aimed to examine the specific role of
nuclear PARG activity in PARP-1 – mediated cell death by
selectively blocking translation of the 111 kDa, nuclear-targeted
isoform using an antisense phosphorodiamidate morpholino oligo-
nucleotide (PMO) targeted to the 59 start of exon 1 (Fig. 1A). PARG
enzymatic activity was used as the primary measure of antisense
PMO efficacy in order to circumvent the difficulties inherent in
identifying full-length PARG and active PARG cleavage products on
standard Western blots [7]. Our findings indicate that selective down-
regulation of the nuclear PARG isoform slows the rate of nuclear
PAR degradation and attenuates PARP-1- mediated cell death.
Materials and Methods
Reagents were purchased from Sigma Chemical Co (St. Louis,
MO) except where noted. Animal studies were performed in
accordance with a protocol approved by the San Francisco
Veterans Affairs Medical Center animal use committee.
Cell cultures
Primary mouse cortical astrocyte cultures were prepared by the
method of Hertz [25] with minor modifications [5].
Morpholino oligonucleotide treatments
The PARG antisense sequence, 59-GGACCCGCAGCACA-
CAGTCCCCC-39, is complementary to the 59 end of exon 1 on
the full length PARG mRNA (GenBank, Accession#
NM_011960), with the exception of the 39nucleotide of the
antisense sequence. The antisense sequence has no significant
complementarity to other sequences in the NCBI Mouse RefSeq
mRNA database. The inverted sequence also has no significant
complementarity to other sequences in the NCBI Mouse RefSeq
mRNA database, and was used as a negative control. For cell
delivery, the PMOs (Gene Tools, Philomath, OR) were mixed
with 1 mM ethoxylated polyethylenimine (EPEI) and diluted into
the culture medium for a 3 hour incubation at 37uC. The cultures
were used for experiments 2 days after PMO treatment.
PARG activity assay
Exoglycosidic PARG activity was measured by the method of
Menard and Poirier [26], with minor modifications [24]. The
enzyme substrate, histone-bound
14C PAR, was prepared using
calf thymus DNA and histones, [U-
14C] NAD (2.84610
22 pmol /
dpm), and purified PARP-1 [24]. The PARG activity assay was
preceded by a 1 hour incubation at 37uC to allow the digestion
endogenous PAR.
14C-labeled PAR was added at a concentration
of 5 mM and the incubation continued for an additional
30 minutes at 37uC. Aliquots were removed at the initial and
ending time points, and reactions were quenched with 0.1%
sodium dodecyl sulfate (SDS). All aliquots were also spiked with
non-radiolabeled ADP-ribose for easy UV detection after thin-
layer chromatography (TLC). The aliquots were spotted onto PEI-
cellulose TLC sheets, which were developed first in 100%
methanol and then in 0.3 M LiCl / 0.9 M acetic acid. The
ADP-ribose spots were cut out and
14C was measured with a liquid
scintillation counter. In some studies, the TLC sheets were imaged
using the Typhoon 9410 system (Amersham) for quantification of
14C-ADP-ribose. Similar results obtained with the two methods.
With either method, ADP-ribose formation was blocked by the
PARG inhibitor gallotannin [10,17] (not shown).
Immunocytochemistry
Confluent astrocytes plated on glass coverslips were fixed in cold
methanol / acetone. The cultures were incubated with a 1:500 dilution
of anti-N-terminal PARG polyclonal antibody (generous gift of Dr.
Myron Jacobson) [24,27], or a 1:1000 dilution of rabbit anti-PAR
(Trevigen), and visualized with fluorescent anti-rabbit or anti-goat IgG.
For some studies, cell nuclei were counterstained with propidium
iodide. Photomicrographs were obtained by confocal microscopy.
Western blots
Cultures were lysed in modified RIPA buffer, applied to a 10%
resolving SDS gel, separated by electrophoresis, and transferred to
PVDF membranes as described [24]. The antibody dilutions were as
follows: mouse monoclonal antibodyto poly(ADP-ribose) (Trevigen ,
Gaithersburg, MD), 1:500; rabbit polyclonal antibody to PARP-1
(Cell Signaling Technology), 1:1500; mouse monoclonal antibody to
porin (Calbiochem, San Diego, CA), 1:1000; mouse monoclonal
antibody to b-actin (Sigma-Aldrich), 1:10,000. Primary antibodies
Figure 1. Nuclear PARG protein expression is reduced by the
PARG antisense PMO targeted to exon 1. (A) The full-length
111 kD protein contains a nuclear localization sequence (NLS) in exon 1
and a nuclear export sequence (NES) near the carboxy terminus. The
anti-PARG antibody targets the peptide fragment indicated [27]. The
PARG antisense PMO was directed to the extreme 59 end of exon 1 of
the full-length PARG mRNA. (B) Astrocytes are immunostained for PARG
(green), and nuclei are counterstained with propidium iodide (red).
Merged images demonstrate a reduction in PARG expression, mainly in
the nuclei, after PARG PMO treatment, as compared to both the no
PMO (Control) condition and the inverted sequence PMO (Control PMO)
condition. Scale bar=20 mm. Images are representative of 6 indepen-
dent experiments with similar results.
doi:10.1371/journal.pone.0004896.g001
Nuclear PARG
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IgG andchemiluminescencedetection. Band intensities on each lane
were normalized to the b-actin bands on the same lane. For
quantification of poly(ADP-ribosyl)ated proteins, the signal over the
entire lane (approximately 20–250 kD) was measured.
Cell fractionation
The separation of nuclear and cytoplasmic components was
performed as described [28]. The purity of the nuclear and
cytoplasmic fractions of each separation were tested in duplicate
using Western blots stained with antibodies to the nuclear marker,
PARP-1, and the mitochondrial marker, porin.
MNNG incubations and cell survival assays
MNNG incubations were performed in a balanced salt solution
(BSS) containing (in mM): KCl, 3.1; NaCl, 134; CaCl2, 1.2;
MgSO4, 1.2; KH2PO4, 0.25; NaHCO3, 15.7; HEPES, 5, glucose,
5. The BSS was equilibrated with a 5% CO2 atmosphere and the
incubations were performed in a 5% CO2 37u incubator.
Incubations were terminated after 60 minutes, except where
noted, by exchange with fresh BSS. Cell survival was evaluated
24 hours later by measuring lactate dehydrogenase (LDH) activity
in cell lysates, using the method of Koh and Choi [29] with
modifications [5]. Cell survival in each well was calculated by
normalizing LDH activity to the mean LDH activity of 4 control
wells from the same 24-well plate.
Statistical analyses
Data are presented as means6standard errors. Statistical
significance was assessed by using the analysis of variance
(ANOVA) followed by the Student-Newman-Keuls test for
comparisons between multiple treatment groups.
Results
The antisense PARG PMO was designed to target the most 59
AUG start codon, which is present only in the full-length 111 kD
mouse PARG mRNA (Fig. 1A). Immunostaining for PARG in
mouse astrocyte cultures treated with antisense PARG PMO
showed a marked and selective loss of immunoreactivity from the
nuclei of the antisense PMO-treated cells, as compared to sister
cultures treated with control (invert sequence) PMO or no PMO
(Fig. 1B). Controls prepared with omission of the anti-PARG
antibody exhibited no immunoreactivity (not shown).
The effect of antisense PARG PMO on full-length PARG
expression was also evaluated with western blots of nuclear and
cytoplasmic cell fractions; however, the western blots revealed only
faint or undetectable full length PARG, consistent with prior
reports of endogenous PARG expression [7,22–24]. We therefore
measured PARG enzymatic activity in the nuclear and cytoplas-
mic cell fractions to evaluate the functional effects of the antisense
PARPG PMO treatment. As shown in Figure 2, the nuclear
PARG specific activity (activity normalized to protein) was
substantially lower in the cells treated with the antisense PMO
than in cells treated with the control PMO or no PMO. By
contrast, there was no significant difference in PARG cytoplasmic
specific activity among the 3 treatment groups. As would be
expected, there was no significant reduction in whole-cell PARG
activity in the antisense-treated cultures, consistent with the
relatively small contribution of nuclear protein to total cell protein
and nuclear PARG activity to total cell PARG activity [7,24].
PARG activity in situ was evaluated by assessing PAR levels at
several time points after inducing PARP-1 activation with the
DNA alkylating agent N-methyl-N9-nitro-N-nitrosoguanidine
(MNNG). In cultures treated with control PMO, PAR immuno-
reactivity peaked at 40–60 minutes after MNNG incubation and
fell to baseline within 2 hours. In cultures treated with antisense
PARG PMO, PAR immunoreactivity peaked at about 60 minutes
and remained detectable for up to 4 hours, consistent with
diminished nuclear PARG activity (Fig. 3A). The PAR immuno-
staining was confined to the nucleus in both control and antisense-
treated cultures. Of note, nuclear condensation was apparent at
the 4 hour time point in cultures treated with control PMO, but
not antisense PARG PMO.
PAR western blots were also used to evaluate the time course of
PAR formation. Cells treated with MNNG showed a distinct band
of PAR immunoreactivity at 116 kD, corresponding to PARP-1
auto-modification, along with less distinct labeling of proteins at a
range of molecular weights, generally above 85 kD (Fig. 3B, D).
This pattern is consistent with prior reports [5,6]. Western blots
prepared from cell lysates prepared at serial time points after
MNNG exposure showed a time course of PAR formation and
degradation pattern similar to that observed with immunostaining.
These serial evaluations also showed the peak level of PAR
formation to be lower in the cells treated with PARG antisense
PMO than in the cells treated with control PMO (Fig. 3C). In
Figure 2. Nuclear PARG activity is selectively reduced by PARG
antisense PMO. (A) Activity assays of whole-cell, nuclear, and
cytoplasmic cell fractions. n=5; * p,0.05. (B) Western blots of cell
fractions showed the nuclear marker PARP-1 confined to the nuclear
fraction and the mitochondrial marker porin confined to the
cytoplasmic fraction. The two lanes show samples prepared from
different culture plates. Blots are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0004896.g002
Nuclear PARG
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performed on nuclear and cytoplasmic cell fractions showed
abundant PAR in the nuclear fractions but no detectable PAR in
the cytoplasm of either the control or antisense PMO - treated
cultures (Fig. 3D). These findings support the results obtained with
the enzymatic assays indicating a reduction in nuclear, but not
cytoplasmic PARG activity in the antisense-treated cultures.
Consistent with the reduced nuclear condensation observed in
Fig. 3A, cells treated with PARG antisense PMO showed reduced
cell death when evaluated 24 hours after MNNG incubations
(Fig. 4). The magnitude of this effect was comparable to that
achieved with the PARP inhibitor 3, 4-dihydro-5-[4-(1-piperidi-
nyl)butoxy]-1(2H)-isoquinolinone (DPQ), suggesting a near-com-
plete abrogation of PARP-1 – mediated cell death by the antisense
PARG PMO.
Discussion
Primary mouse astrocytes were treated with an antisense PMO
targeted to exon 1 of full-length PARG to suppress expression of
Figure 3. PARG antisense PMO slows PAR degradation. Cultures were incubated with 50 mM MNNG. For observations at time points of
60 minutes or less, incubation with MNNG was continuous. For observations at time points beyond 60 minutes, MNNG was washed out at the 60-
minute time point. (A) Immunostaining for PAR (green) in astrocytes at the designated time points. Nuclei are counterstained red with propidium
iodide, and the images are merged. The cultures treated with antisense PARG PMO show prolonged nuclear PAR immunostaining relative to those
treated with control PMO, and show less nuclear condensation at the 4 hour time point. Scale bar=40 mm. Results are representative of 4
independent experiments. (B) PAR Western blots from cells treated with MNNG show prolonged elevations in PAR immunoreactivity in the cultures
treated with PARG antisense PMO. (C) Graph shows quantified data. n=3, *p,0.05. (D) PAR Western blots prepared from nuclear and cytoplasmic
cell fractions showed PAR detectable only in the nuclear fraction. These blots are overexposed, relative to the blots shown in Fig. 3B, to increase
sensitivity.
doi:10.1371/journal.pone.0004896.g003
Nuclear PARG
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showed down-regulation of both nuclear PARG immunoreactivity
and nuclear PARG enzymatic activity, without significant
alteration in cytoplasmic PARG activity. When treated with the
genotoxic agent MNNG to induced PARP-1 activation, the
antisense-treated cells showed a delayed rate of nuclear PAR
degradation, reduced nuclear condensation, and reduced cell
death. These findings support prior reports that full-length PARG
is preferentially localized to the nucleus [7,21], and provide a
novel tool for investigating potential isoform-specific functions of
PARG. These results also suggest a key role for nuclear PARG
activity in PARP-1 – mediated cell death.
The PARG gene can be processed into three splice variants that
yield proteins of 111 kD, 102 kD, and 99 kD(Fig. 1A). Only the full
length 111 kD PARG isoform is normally found in the cell nucleus,
and this localization is attributed to a NLS motif encoded by the 59
region of exon 1 in the full length PARG mRNA [7,8,21]. The
selective reduction in nuclear PARG activity observed in cells
treated with antisense PMO targeting the 59 terminus of PARG
exon 1 is thus consistent with a selective down-regulation of the full-
length PARG isoform. However, evidence suggests that PARG
normally found in the cytoplasm may under some conditions traffic
into the nucleus [7,30]. We thus cannot entirely exclude the
possibility that the antisense treatment reduces expression of other
PARG species with access to the nucleus, but the absence of any
change in cytoplasmic PARG activity weighs against this possibility.
The morpholino PMO antisense approach used here to
suppress nuclear PARG protein expression differs from siRNA
and other antisense approaches in that it inhibits mRNA
translation by a mechanism independent of mRNA destruction
[31,32]. Antisense PMOs have previously been used to selectively
suppress translation of splice variant mRNA species, and evidence
suggests that the PMO antisense approach has less off-target
effects than siRNA and other antisense approaches [32,33].
Nevertheless, the results presented here cannot entirely exclude
the possibility the antisense PMO directed against the full-length
PARG affects nuclear PARG activity by a mechanism indepen-
dent of PARG protein expression, but the selective loss of nuclear
PARG activity without loss of cytoplasmic PARG activity again
weighs against this possibility.
Cellular PAR levels are the net result of the competing processes
of PAR formation, primarily by PARP-1, and PAR degradation,
by PARG. The prolonged increase in cellular PAR levels following
MNNG-induced PARP-1 activation observed in cultures treated
with antisense PARG PMO is consistent with reduced nuclear
PARG activity. However, a somewhat surprising result was that
the peak level of PAR formation was not elevated in these cultures,
and was in fact reduced relative to the cultures treated with control
PMO (Fig. 3C). Given that PARP-1 can be inhibited by PAR
auto-modification [2], it is possible that the reduced peak PAR
level observed in the PARG antisense-treated cultures is due to
increased or prolonged PAR formation on PARP-1 with resultant
reduced PARP-1 activity in these cultures. Reduced PARP-1
activity might also contribute to the reduced cell death observed in
the antisense PARG-treated cultures. However, recent studies
have also identified complex physical interactions between PARP-
1, PARG, and other nuclear proteins [34,35], and these findings
raise the alternative possibilities that reduced nuclear PARG
protein could influence PARP-1 activity by through these or other,
more indirect interactions.
Confluent primary astrocytes cultures area useful model for these
studies because these cells are homogeneous, differentiated, slowly-
dividing, and non-neoplastic, with a correspondingly low level of
spontaneous apoptosis. Astrocytes are the most numerous cell type
in mammalian brain. Prior studies have extensively characterized
the PARP-1 - mediated cell death pathway in this cell type, and
shown that PARP-1 - mediated cell death can be attenuated by
pharmacological PARG inhibitors [5,10,11,24,36–38].
Results of the present study can be compared to recent reports
in which PARG protein expression was reduced by other methods
in other model systems. Ablation of PARG enzymatic activity by
gene disruption in the mouse causes massive PAR accumulation
and embryonic lethality [6]. Cortes et al. generated a viable mouse
in which a truncated 60 kDa PARG enzyme was expressed in
place of the full length 110 kDa enzyme as a result of the targeted
deletion of the exons 2 and 3 in the regulatory domain [19]. Cells
from these mice showed reduced PARG activity in the nuclei, but
markedly increased activity in the mitochondrial fraction.
Surprisingly, cells from these mice showed evidence of reduced,
rather than increased auto-modification of PARP-1, possibly due
to abnormal interaction between the truncated PARG and PARP-
1 or XRCC1 [19,20,35]. The reduced PARP-1 auto-modification
was associated with increased cell death and mortality under
conditions that trigger PARP-1 induced cell death. Most germane
to the present study is the siRNA knockdown of PARG in HeLa
cells reported by Malanga and colleagues [16]. These authors
achieved a roughly 85% reduction in PARG enzymatic activity in
both the cytoplasmic and nuclear compartments. Cells with
reduced PARG activity showed prolonged PAR immunoreactivity
and reduced cell death after exposure to H2O2, similar to the
Figure 4. PARP-1 mediated cell death is reduced by PARG
antisense PMO. Cell survival was assessed 24 hours after 60-minute
incubations with 50 mM MNNG. Cell death was comparably reduced by
co-incubation with the PARP inhibitor, DPQ. Data shown are
representative of 5 experiments, each with n=3. **p,0.01 vs. 50 mM
MNNG alone.
doi:10.1371/journal.pone.0004896.g004
Nuclear PARG
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PARG activity. However, in contrast to the present results, PARG
down-regulation did not increase viability in response to MNNG,
a difference that may be attributable to PARP-1 – independent
cell death pathways that can be triggered in dividing tumor cells by
low concentrations of MNNG [39] or to the reduction in
cytoplasmic PARG activity in the siRNA study.
The present results indicate that selective reduction of nuclear
PARG activity can attenuate PARP-1-induced astrocyte death,
but the mechanism of this effect remains to be established. Given
what is known about PARP-1 cell death pathway, possibilities
include 1) slowed PAR liberation from the nucleus [4] ; 2) slowed
NAD
+ consumption, due to reducing PAR turnover at acceptor
sites or to increased PARP-1 auto-modification [5]; and 3) effects
on PAR-regulated transcription factors [40]. Further work will be
required to distinguish between these or other possibilities.
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